SCHEMBL20129080

SCHEMBL20129080

CC(C)(C)OC(=O)COCCOCCOCCOCCOc1ncc(Br)cc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 2/20 0.44
AAK1 Q2M2I8 1/20 0.36
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
KDM4E B2RXH2 1/20 0.32
GLA P06280 1/20 0.32
S1PR4 O95977 1/20 0.31
CNR2 P34972 1/20 0.31
APP P05067 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
LATS1 O95835 1/20 0.30
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129078 0.79 SSTR4 (0.41) SSTR4APP
SCHEMBL20213958 0.79 SSTR4 (0.41) SSTR4AAK1KDM4EGLAS1PR4
SCHEMBL20120517 0.79 SSTR4 (0.41) SSTR4APP
SCHEMBL6900352 0.77 SSTR4 (0.44) SSTR4AAK1
SCHEMBL31108106 0.76 CCNB2 (0.34) AAK1KDM4ELATS1
SCHEMBL22638138 0.76 SSTR4 (0.44) SSTR4AAK1KDM4ES1PR4CNR2
SCHEMBL29749337 0.76 SSTR4 (0.44) SSTR4AAK1KDM4ES1PR4CNR2
SCHEMBL16520058 0.75 SSTR4 (0.49) SSTR4
SCHEMBL22907011 0.75 DGAT1 (0.43) KDM4EAPPLATS1
SCHEMBL31411075 0.75 DGAT1 (0.43) KDM4EAPPLATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN SSTR4 4723/4885AAK1 2106/4885PSEN1 18/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 SSTR4 4810/4885AAK1 2171/4885PSEN1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.